first_pagesettingsOrder Article Reprints Open AccessReview COVID-19 in Patients with Hematologic Diseases by Ilaria Carola Casetti 1ORCID,Oscar Borsani 1,2ORCID andElisa Rumi 1,2,*ORCID 1 Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy 2 Division of Hematology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy * Author to whom correspondence should be addressed. Biomedicines 2022, 10(12), 3069; https://doi.org/10.3390/biomedicines10123069 Received: 4 November 2022 / Revised: 22 November 2022 / Accepted: 25 November 2022 / Published: 29 November 2022 (This article belongs to the Special Issue Biomedicines: 10th Anniversary) Download Browse Figures Review Reports Versions Notes Abstract The COVID-19 outbreak had a strong impact on people’s lives all over the world. Patients with hematologic diseases have been heavily affected by the pandemic, because their immune system may be compromised due to anti-cancer or immunosuppressive therapies and because diagnosis and treatment of their baseline conditions were delayed during lockdowns. Hematologic malignancies emerged very soon as risk factors for severe COVID-19 infection, increasing the mortality rate. SARS-CoV2 can also induce or exacerbate immune-mediated cytopenias, such as autoimmune hemolytic anemias, complement-mediated anemias, and immune thrombocytopenia. Active immunization with vaccines has been shown to be the best prophylaxis of severe COVID-19 in hematologic patients. However, the immune response to vaccines may be significantly impaired, especially in those receiving anti-CD20 monoclonal antibodies or immunosuppressive agents. Recently, antiviral drugs and monoclonal antibodies have become available for pre-exposure and post-exposure prevention of severe COVID-19. As adverse events after vaccines are extremely rare, the cost–benefit ratio is largely in favor of vaccination, even in patients who might be non-responders; in the hematological setting, all patients should be considered at high risk of developing complications due to SARS-CoV2 infection and should be offered all the therapies aimed to prevent them.

COVID-19 in Patients with Hematologic Diseases

Casetti IC;Borsani O;Rumi E.
2022-01-01

Abstract

first_pagesettingsOrder Article Reprints Open AccessReview COVID-19 in Patients with Hematologic Diseases by Ilaria Carola Casetti 1ORCID,Oscar Borsani 1,2ORCID andElisa Rumi 1,2,*ORCID 1 Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy 2 Division of Hematology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy * Author to whom correspondence should be addressed. Biomedicines 2022, 10(12), 3069; https://doi.org/10.3390/biomedicines10123069 Received: 4 November 2022 / Revised: 22 November 2022 / Accepted: 25 November 2022 / Published: 29 November 2022 (This article belongs to the Special Issue Biomedicines: 10th Anniversary) Download Browse Figures Review Reports Versions Notes Abstract The COVID-19 outbreak had a strong impact on people’s lives all over the world. Patients with hematologic diseases have been heavily affected by the pandemic, because their immune system may be compromised due to anti-cancer or immunosuppressive therapies and because diagnosis and treatment of their baseline conditions were delayed during lockdowns. Hematologic malignancies emerged very soon as risk factors for severe COVID-19 infection, increasing the mortality rate. SARS-CoV2 can also induce or exacerbate immune-mediated cytopenias, such as autoimmune hemolytic anemias, complement-mediated anemias, and immune thrombocytopenia. Active immunization with vaccines has been shown to be the best prophylaxis of severe COVID-19 in hematologic patients. However, the immune response to vaccines may be significantly impaired, especially in those receiving anti-CD20 monoclonal antibodies or immunosuppressive agents. Recently, antiviral drugs and monoclonal antibodies have become available for pre-exposure and post-exposure prevention of severe COVID-19. As adverse events after vaccines are extremely rare, the cost–benefit ratio is largely in favor of vaccination, even in patients who might be non-responders; in the hematological setting, all patients should be considered at high risk of developing complications due to SARS-CoV2 infection and should be offered all the therapies aimed to prevent them.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1477636
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact